Immunohistochemical Analysis for the Expression of DR5 TRAIL Receptor and p53 in Non-small Cell Lung Cancer |
Lee, Kye-Young
(Department of Internal Medicine, Konkuk University School of Medicine)
Lee, Jung-Hyun (Department of Internal Medicine, Konkuk University School of Medicine) Kim, Sun-Jong (Department of Internal Medicine, Konkuk University School of Medicine) Yoo, Kwang-Ha (Department of Internal Medicine, Konkuk University School of Medicine) |
1 | Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7: 383-5 DOI ScienceOn |
2 | Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63 DOI ScienceOn |
3 | Bremer E, van Dam G, Kroesen BJ, Leij L, Helfrich W. Targeted induction of apoptosis cancer therapy: current progress and prospects. Trends Mol Med 2006;12: 382-93 DOI ScienceOn |
4 | Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999;59:2747-53 |
5 | Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000;164:3961-70 DOI |
6 | Oren M. Decision making by p53: life, death, and cancer. Cell Death Differ 2003;10:431-42 DOI ScienceOn |
7 | Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000;14:1509- 13 DOI |
8 | Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3 DOI ScienceOn |
9 | Liu X, Yue P, Khuri FR, Sun SY. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 2005;65:9169-75 DOI ScienceOn |
10 | Jang SH, Seol JY, Kim CH, Yoo CG, Kim YW, Han SK, et al. Additive effect of TRAIL and p53 gene transfer on apoptosis of human lung cancer cell lines. Int J Mol Med 2004;13:181-6 |
11 | Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104: 155-62 DOI ScienceOn |
12 | El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001;8:1066-75 DOI |
13 | Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003;9:3397-405 |
14 | Gajewski TF. On the TRAIL toward death receptorbased cancer therapeutics. J Clin Oncol 2007;25:1305-7 DOI ScienceOn |
15 | Wu WG, Soria JC, Wang L, Kemp BL, Mao L. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. Anticancer Res 2000;20: 4525-9 |
16 | Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-5 DOI ScienceOn |
17 | Cretney E, Uldrich AP, Berzins SP, Strasser A, Godfrey DI, Smyth MJ. Normal thymocyte negative selection in TRAIL-deficient mice. J Exp Med 2003;198:491-6 DOI ScienceOn |
18 | Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol 2001;18:241-7 |
19 | Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001;61:2704-12 |
20 | Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8 DOI ScienceOn |
21 | Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999;59:5683-6 |